SSPL’s journey reflects its DNA and pedigree as a truly global, path-breaking research-oriented company. Its vision is to take science to market, and it has established resilience in complex, long-drawn research areas by enduring a 20-year journey to bring its products to suffering patients. The company’s mission is to continue bringing new health solutions to patients suffering worldwide from diseases that currently have no solutions available.
Overall, SSPL’s impressive record of research, global FDA accreditations, and collaborations with leading universities worldwide demonstrate its commitment to bringing innovative solutions to complex global health challenges.

Women health and Rare Neglected Disease:

We have attained global path-breaking niche success in areas of rare and neglected disease concerned with women bladder health.
Rare and neglected diseases are diseases that primarily affect people in low- and middle-income countries and are often overlooked by the global health community. Neglected diseases are characterized by a lack of research and development funding, limited access to affordable treatments, and inadequate healthcare infrastructure.
Women bladder disease (Interstitial cystitis (IC) /Bladder Pain Syndrome (BPS)), also known as painful bladder syndrome, is a chronic condition that causes bladder pain and discomfort. It is more common in women than men, and the exact cause is unknown. Researchers believe it may be related to an issue with the protective lining of the bladder, while others believe it may be related to an autoimmune response or nerve-related issues.
While there is no cure for interstitial cystitis, with appropriate management and care, most people with the condition are able to reduce their symptoms and lead fulfilling lives.

Supply Chain Diversification:

Our company has been a prominent player in the pharmaceutical industry for over 50+ years, with expertise in polysaccharide chemistry for over 20 years. Our extensive experience in sustaining complex chemistry and research has fueled our vision to manufacture complex vitamins in India. To achieve this goal, we are seeking strategic partners in India to collaborate with us and diversify our supply chain beyond China.
This move will not only increase our resilience but also our competitiveness in the global marketplace. We are adopting the China Plus One (CPO) manufacturing strategy, which aims to diversify the production base beyond China. With this approach, we are confident that we can ensure a steady supply of essential lifesaving medicines and contribute to the growth of the Indian pharmaceutical industry.